July 20, 2009 – Baxter International Inc. is working to discover a drug that would reduce the number of infusions a person with hemophilia needs. Flamel Technologies SA, of France, will receive $3.5 million dollars to do the research for Baxter.
The goal of the study is to discover longer acting blood clotting factors. If these longer acting factors are found then the number infusions would decrease because the clotting factor would stay in the blood longer.
Source: The Associated Press